Addendum
Enfortumab vedotin (urothelial carcinoma) – Addendum to Commission A22-61
Report documents
-
Addendum
Enfortumab vedotin (urothelial carcinoma) – Addendum to Commission A22-61
Additional information
Federal Joint Committee (G-BA)
2022-12-01 A G-BA decision was published.
Project details
- Project no.
- A22-107
- Commission
- Commission awarded on 11.10.2022 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Enfortumab vedotin (urothelial cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Enfortumab vedotin (urothelial cancer, neoadjuvant + adjuvant) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed